Novo: We want to be to hemophilia, what we are to diabetes
Novo Nordisk does not just focus on treatment, but on disease-care in a larger scope, when the company develops medicine for hemophilia patients. The idea has been lifted from the company’s approach to diabetes medicine.
af KRESTEN MORTEN MUNKSGAARD
In order to break into the market for hemophilia medicine, Novo Nordisk will make use of the same approach the company used to create its position on the diabetes market, says Vice President for Medical and Science, in Haemostasis Global Development, Stephanie Seremitis, who has just taken part in the World Federation of Hemophilia 2012 World Congress held in Paris from July 9-12.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
